Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000215890

Medchemexpress LLC Eganelisib (IPI-549) | 1693758-51-8 | MFCD30533720 | 99.7% | 528.56 g·mol⁻¹ | C30H24N8O2 | 10 MG
SDP

Catalog No. 5000215890
Encompass_Preferred

Eganelisib (IPI-549) is an orally bioavailable, selective small-molecule inhibitor of the gamma isoform of phosphoinositide 3-kinase (PI3Kγ) used in research and preclinical immuno-oncology studies. It demonstrates potent PI3Kγ inhibition (IC50 ≈ 16 nM) and >100-fold selectivity over other lipid and protein kinases.

  • Potent PI3Kγ inhibition with IC50 ≈ 16 nM.
  • Greater than 100-fold selectivity over other lipid and protein kinases.
  • High reported purity suitable for research applications.
  • Known molecular weight and CAS for unambiguous identification.
  • Supplied in small quantities appropriate for preclinical studies.

Catalog No. 50-002-15890 Supplier Medchemexpress LLC Supplier No. HY10071610MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Eganelisib (IPI-549) is an orally bioavailable, selective small-molecule inhibitor of the gamma isoform of phosphoinositide 3-kinase (PI3Kγ) used in research and preclinical immuno-oncology studies. It demonstrates potent PI3Kγ inhibition (IC50 ≈ 16 nM) and >100-fold selectivity over other lipid and protein kinases.

  • Potent PI3Kγ inhibition with IC50 ≈ 16 nM.
  • Greater than 100-fold selectivity over other lipid and protein kinases.
  • High reported purity suitable for research applications.
  • Known molecular weight and CAS for unambiguous identification.
  • Supplied in small quantities appropriate for preclinical studies.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.